EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) Fundamental Analysis & Valuation

TSX:EPRX • CA29842P1053

Current stock price

9.44 CAD
-0.35 (-3.58%)
Last:

This EPRX.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. EPRX.CA Profitability Analysis

1.1 Basic Checks

  • EPRX had negative earnings in the past year.
  • In the past year EPRX has reported a negative cash flow from operations.
  • In the past 5 years EPRX always reported negative net income.
  • In the past 5 years EPRX always reported negative operating cash flow.
EPRX.CA Yearly Net Income VS EBIT VS OCF VS FCFEPRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • EPRX's Return On Assets of -44.78% is fine compared to the rest of the industry. EPRX outperforms 60.87% of its industry peers.
  • The Return On Equity of EPRX (-47.02%) is better than 69.57% of its industry peers.
Industry RankSector Rank
ROA -44.78%
ROE -47.02%
ROIC N/A
ROA(3y)-85.67%
ROA(5y)-84.11%
ROE(3y)-465.58%
ROE(5y)-338.07%
ROIC(3y)N/A
ROIC(5y)N/A
EPRX.CA Yearly ROA, ROE, ROICEPRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1K -1K -2K

1.3 Margins

  • EPRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EPRX.CA Yearly Profit, Operating, Gross MarginsEPRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. EPRX.CA Health Analysis

2.1 Basic Checks

  • EPRX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for EPRX has been increased compared to 5 years ago.
  • EPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EPRX.CA Yearly Shares OutstandingEPRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
EPRX.CA Yearly Total Debt VS Total AssetsEPRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • EPRX has an Altman-Z score of 56.28. This indicates that EPRX is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of EPRX (56.28) is better than 100.00% of its industry peers.
  • There is no outstanding debt for EPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 56.28
ROIC/WACCN/A
WACCN/A
EPRX.CA Yearly LT Debt VS Equity VS FCFEPRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 15.12 indicates that EPRX has no problem at all paying its short term obligations.
  • EPRX's Current ratio of 15.12 is amongst the best of the industry. EPRX outperforms 95.65% of its industry peers.
  • A Quick Ratio of 15.12 indicates that EPRX has no problem at all paying its short term obligations.
  • EPRX has a Quick ratio of 15.12. This is amongst the best in the industry. EPRX outperforms 95.65% of its industry peers.
Industry RankSector Rank
Current Ratio 15.12
Quick Ratio 15.12
EPRX.CA Yearly Current Assets VS Current LiabilitesEPRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. EPRX.CA Growth Analysis

3.1 Past

  • The earnings per share for EPRX have decreased strongly by -39.98% in the last year.
EPS 1Y (TTM)-39.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-84.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 19.08% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y42.92%
EPS Next 2Y30.57%
EPS Next 3Y15.53%
EPS Next 5Y19.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPRX.CA Yearly Revenue VS EstimatesEPRX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
EPRX.CA Yearly EPS VS EstimatesEPRX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2 3

More info and screens

Find the best growth stocksShow best growing peers

0

4. EPRX.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for EPRX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EPRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EPRX.CA Price Earnings VS Forward Price EarningsEPRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EPRX.CA Per share dataEPRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

  • EPRX's earnings are expected to grow with 15.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.57%
EPS Next 3Y15.53%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EPRX.CA Dividend Analysis

5.1 Amount

  • EPRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EPRX.CA Fundamentals: All Metrics, Ratios and Statistics

EUPRAXIA PHARMACEUTICALS INC

TSX:EPRX (3/26/2026, 7:00:00 PM)

9.44

-0.35 (-3.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)N/A
Inst Owners31.44%
Inst Owner ChangeN/A
Ins Owners15.89%
Ins Owner ChangeN/A
Market Cap562.15M
Revenue(TTM)N/A
Net Income(TTM)-38.58M
Analysts82.22
Price Target14.96 (58.47%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-67.51%
Min EPS beat(2)-116.44%
Max EPS beat(2)-18.58%
EPS beat(4)0
Avg EPS beat(4)-50.11%
Min EPS beat(4)-116.44%
Max EPS beat(4)-18.58%
EPS beat(8)3
Avg EPS beat(8)-30.91%
EPS beat(12)6
Avg EPS beat(12)-19.98%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)21.11%
EPS NQ rev (1m)-30.43%
EPS NQ rev (3m)-6.78%
EPS NY rev (1m)-25.26%
EPS NY rev (3m)-7.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.95
P/tB 4.95
EV/EBITDA N/A
EPS(TTM)-1.99
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.66
OCFYN/A
SpS0
BVpS1.91
TBVpS1.91
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -44.78%
ROE -47.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-85.67%
ROA(5y)-84.11%
ROE(3y)-465.58%
ROE(5y)-338.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 247.79%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.12
Quick Ratio 15.12
Altman-Z 56.28
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)134.74%
Cap/Depr(5y)191.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-39.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-84.29%
EPS Next Y42.92%
EPS Next 2Y30.57%
EPS Next 3Y15.53%
EPS Next 5Y19.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-44.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.5%
EBIT Next 3Y12.81%
EBIT Next 5Y29.94%
FCF growth 1Y3.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.81%
OCF growth 3YN/A
OCF growth 5YN/A

EUPRAXIA PHARMACEUTICALS INC / EPRX.CA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for EUPRAXIA PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 3 / 10 to EPRX.CA.


What is the valuation status for EPRX stock?

ChartMill assigns a valuation rating of 0 / 10 to EUPRAXIA PHARMACEUTICALS INC (EPRX.CA). This can be considered as Overvalued.


Can you provide the profitability details for EUPRAXIA PHARMACEUTICALS INC?

EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) has a profitability rating of 1 / 10.


What is the expected EPS growth for EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) stock?

The Earnings per Share (EPS) of EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) is expected to grow by 42.92% in the next year.